More information about text formats
To the editor and auther Kivela et al.:
We thank the authors of the article “Intravitreal Methotrexate for Retinoblastoma” published in Ophthalmology in 2011 for their letter to the editor and adjustment of our discussion in our paper. As was found in your experience, as well as ours, intravitreal chemotherapy plays an important role in the treatment of retinoblastoma outside of its currently accepted use for intravitreal seeds. We look forward to hearing about your continued successful experience with intravitreal melphalan for use beyond intravitreal seeds.
In their report, entitled “Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds“, Abramson and corkers report on the successful use of intravitreal chemotherapy in 52 patients for subretinal seeds and recurrent retinal tumours . They state that, prior to their experience, intravitreal chemotherapy had been used exclusively to control persistent or recurrent vitreous seeding in retinoblastoma that had been refractory to systemic intravenous or intra-arterial chemotherapy.
In fact, intravitreal chemotherapy as an adjuvant treatment for both subretinal seeds and recurrent retinal tumours, including its use instead of systemic chemotherapy in the setting of chemothermotherapy for small unresponsive primary retinoblastomas, has been in regular use already for a decade at the Ocular Oncology Service, Helsinki University Eye Hospital. Indeed, three of the first four patients that we reported during the congress of the International Society of Ocular Oncology in 2009 , and published in 2011 , received intravitreal methotrexate for reasons other than vitreous seeds. Subsequent experience with intravitreal chemotherapy with methotrexate and, later, with melphalan has strengthened our initial findings, as does the comprehensive report of Abramson and coworkers.
1. Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol 2018 Jun 6. pii: bjophthalmol-...
1. Abramson DH, Ji X, Francis JH, et al. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds. Br J Ophthalmol 2018 Jun 6. pii: bjophthalmol-2018-312037. doi: 10.1136/bjophthalmol-2018-312037.
2. Kivelä T, Eskelin S, Lindahl P, Majander A. Intravitreal methotrexate monotherapy as salvage treatment for recurrent retinoblastoma after standard chemoreduction. In: ISOO Metting 2009: Programme and Abstracts, p. 279. http://www.xcdsystem.com//isoo/webimages/pdf%20%236%20isoo%202009%20camb... (accessed on November 1, 2018)
3. Kivelä T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology 2011;118(8):1689, 1689.e1-6. doi: 10.1016/j.ophtha.2011.02.005.